Anti-TNF ADCC Enhanced Antibody (AVX-470) is an ADCC enhanced antibody produced by our Afuco™ platform. AVX-470 is a novel polyclonal antibody specific for human TNF used for Inflammatory bowel disease (IBD). IBD is a chronic inflammatory disease of the gastrointestinal tract, which is currently treated with injected monoclonal antibodies specific for tumor necrosis factor (TNF).
Figure 1 TNF-binding potency, TNF-binding affinity and TNF-neutralizing potency of AVX-470 and AVX-470m.
(A) TNF-binding potency of AVX-470 and control Ig measured in duplicate wells by ELISA on rhTNF-coated plates. Representative experiment. AVX-470 mean titer = 1.2 µg/mL in 8 experiments. (B) TNF-binding potency of AVX-470m and control Ig measured in duplicate wells by ELISA on rmTNF-coated plates. AVX-470m mean titer = 4.3 µg/mL in 3 experiments (C) TNF-binding affinity in a representative experiment of AVX-470A affinity-purified antibody and infliximab for human TNF analyzed in duplicate wells by competition ELISA. IC50 concentration is an estimate of affinity. AVX-470A mean IC50 = 260 pM from 2 experiments; infliximab mean IC50 = 280 pM from 2 experiments. (D) Affinity of AVX-470mA affinity-purified antibody and TN3 antibody for murine TNF in a representative experiment analyzed in duplicate wells by competition ELISA. AVX-470mA IC50 = 550 pM; TN3 IC50 = 26 pM. Means from 2 experiments. (E) TNF-neutralization potency of AVX-470 measured in an L929 cell-based assay. Representative experiment. AVX-470 mean IC50 = 22 µg/mL over 31 experiments (F) TNF-neutralization potency of AVX-470A and infliximab measured in an L929 cell-based assay. Representative of 2 separate experiments. AVX-470A mean IC50 = 50 ng/mL; infliximab mean IC50 = 56 ng/mL.
Bhol, K. C., Tracey, D. E., Lemos, B. R., Lyng, G. D., Erlich, E. C., Keane, D. M.,... & Fox, B. S. (2013). AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflammatory bowel diseases,19(11), 2273-2281.
Figure 2 Oral AVX-470m efficacy in murine IBD models as assessed by endoscopy.
(A) Representative endoscopic images in TNBS-colitis (Day 5). Preventative treatment with saline, AVX-470m (10 mg/day shown) or control Ig (3 mg/day). (B) Representative endoscopic images in DSS-colitis (Day 12). Preventative treatment with saline, AVX-470m (10 mg/day shown) or control Ig (3 mg/day). (C) Endoscopy scores in TNBS-colitis (Day 5). 8-12 mice per group. *, P <.05 compared with saline-treated group. (D) Endoscopy scores in DSS-colitis prevention (Day 12). 10-12 mice per group. *, P <.05 compared with control Ig group. (E) Endoscopy scores in established DSS-colitis study (Day 19). 12-15 mice per group. *, P <.05 compared with salinetreated group.
Bhol, K. C., Tracey, D. E., Lemos, B. R., Lyng, G. D., Erlich, E. C., Keane, D. M.,... & Fox, B. S. (2013). AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflammatory bowel diseases,19(11), 2273-2281.
Figure 3 Oral bovine Ig localizes in colon tissues, but with minimal systemic exposure, in mice with DSS-induced colitis.
(A) Representative sections of colon tissues showing localization of bovine Ig by IHC (brown staining). Colon sections were from mice with DSS-induced colitis on Day 19 treated with AVX-470m (10 mg/day) or control Ig (3 mg/day) or from normal mice without colitis (top right panel) treated for 28 days with AVX-470m (10 mg/day). Colon sections show mucosa and lamina propria regions except lower left panel shows muscularis mucosa (top) and submucosa (bottom) regions. (B) Pie chart of sera from oral bovine Ig-treated mice showing the percentage positive for bovine Ig by ELISA. Sera were obtained from individual mice on the day of sacrifice from TNBS and DSS colitis prevention studies and three established DSS-induced colitis studies with oral administration of AVX-470m or control Ig.
Bhol, K. C., Tracey, D. E., Lemos, B. R., Lyng, G. D., Erlich, E. C., Keane, D. M.,... & Fox, B. S. (2013). AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflammatory bowel diseases,19(11), 2273-2281.
Figure 4 Oral AVX-470m inhibits colon inflammation and inflammatory marker expression in established DSS-induced colitis.
(A) H&E stained colon sections were scored for the presence of inflammatory aggregates and the degree of diffuse inflammation on a scale of 0-4; magnification 400×. (B) Representative IHC staining of Day 19 colon sections for the macrophage marker CD68. Shown are representative sections from normal mice (No DSS), or mice treated with saline, AVX-470m or control Ig. (C) IHC scores for the saline and AVX-470m (10 mg/day) treatment groups on a scale of 0-4 for a panel of inflammation markers: MPO (myeloperoxidase, a neutrophil granulocyte marker); CD3, a pan T-cell marker; and cytokines TNF, IFNγ, IL-1β, IL-6 and IL-12p40 (which detects IL-12 and IL-23). (D) Representative IHC staining for TNF in Day 19 colon sections. Shown are representative sections from normal mice (No DSS), or mice treated with saline, AVX-470m or control Ig. (E) Relative mRNA expression levels of a panel of inflammation markers as measured by qRT-PCR for the saline and AVX-470m (10 mg/day) treatment groups. *, P <.05 for treatment groups compared with the saline-treated group. Results are expressed as mean ± SEM.
Bhol, K. C., Tracey, D. E., Lemos, B. R., Lyng, G. D., Erlich, E. C., Keane, D. M.,... & Fox, B. S. (2013). AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflammatory bowel diseases,19(11), 2273-2281.
Figure 5 Measurement of bovine Ig in stool homogenates after 4 weeks of treatment with AVX-470 or placebo.
(A) Dose-dependent increase in the percentage of patients with detectable levels of bovine Ig in stool at Week 4. Bovine Ig in the placebo group was presumably from dietary sources. Patient numbers varied between the groups: placebo, n = 8; AVX-470 0.2g/day, n = 8; 1.6g/day, n = 11; 3.5g/day, n = 6.
Harris, M. S., Hartman, D., Lemos, B. R., Erlich, E. C., Spence, S., Kennedy, S.,... & Fox, B. S. (2016). AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial. Journal of Crohn's and Colitis, 10(6), 631-640.
Figure 6 Serum human anti-bovine Ig antibody (HABA) levels. Mean percentage inhibition of optical density over time for AVX-470 groups and pooled placebo.
Weeks 1-4 represent the treatment period; Week 5 corresponds to the follow-up visit 1 week post-cessation of treatment (A) pooled placebo; (B) AVX-470 0.2g/day; (C) AVX-470 1.6g/day; (D) AVX-470 3.5g/day. Each line represents an individual patient. Week 0 = baseline samples collected prior to the first dose of AVX-470. Screening cut point = 0.162 OD (dotted line) based on 55 normal serum samples.
Harris, M. S., Hartman, D., Lemos, B. R., Erlich, E. C., Spence, S., Kennedy, S.,... & Fox, B. S. (2016). AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial. Journal of Crohn's and Colitis, 10(6), 631-640.
Figure 7 Changes in serum CRP and IL-6 were also most pronounced in the 3.5g/day dose group
(A) Changes in CRP levels for each patient at Week 4 vs baseline (mean ± SE). Log-transformed changes for each treatment group were compared by 2-sided, 2-sample t -tests († p = 0.052, 3.5g/day vs placebo). (B) Raw change (mean ± SE) in IL-6 levels compared by ANCOVA as a function of treatment adjusting for baseline for all dose groups (p = 0.069) and AVX-470 3.5g/day vs placebo (†† p = 0.015).
Harris, M. S., Hartman, D., Lemos, B. R., Erlich, E. C., Spence, S., Kennedy, S.,... & Fox, B. S. (2016). AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial. Journal of Crohn's and Colitis, 10(6), 631-640.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1076z | Mouse Anti-TNF Recombinant Antibody (clone 18C3) | ELISA, FC, FuncS | Mouse IgG1, κ |
HPAB-0007-YC | Human Anti-TNF Recombinant Antibody (clone cA2) | ELISA, Neut | Chimeric (mouse/human) IgG1 |
MOB-169CQ | Goat Anti-TNF Polyclonal Antibody, Biotin | WB, ELISA(Det), ICC | Goat IgG |
MOB-170CQ | Mouse Anti-TNF Recombinant Antibody (clone YC146), Biotin | Neut, ELISA, ICC, FC | Mouse IgG1, κ |
HPAB-0675-CN | Human Anti-TNF Recombinant Antibody (HPAB-0675-CN) | ELISA, Neut | Humanized IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-768 | Anti-TNF alpha Recombinant Antibody (Nerelimomab) | FuncS, IF, Neut, ELISA, FC, IP, ICC | IgG1 |
TAB-311CT | Anti-Human TNFα/RANKL Recombinant Antibody (8G12) | Neut, ELISA, FC | |
TAB-112CQ-S(P) | Anti-Human TNF Recombinant Antibody scFv Fragment (A10G10) | ELISA, WB | |
TAB-271CQ-S(P) | Rabbit Anti-TNF Recombinant Antibody; scFv Fragment (TAB-271CQ-S(P)) | ELISA, WB | Rabbit scFv |
TAB-271CQ-F(E) | Rabbit Anti-TNF Recombinant Antibody; Fab Fragment (TAB-271CQ-F(E)) | ELISA, WB | Rabbit Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-006 | Anti-Human TNF Recombinant Antibody (Infliximab) | IF, IP, Neut, FuncS, ELISA, FC, WB | IgG1 - kappa |
TAB-148CQ | Anti-Human TNF Recombinant Antibody | ELISA | Chimeric antibody (mouse/human) |
TAB-148CQ-S(P) | Anti-Human TNF Recombinant Antibody scFv Fragment | ELISA | Chimeric antibody (mouse/human) |
TAB-402CQ-S(P) | Mouse Anti-TNF Recombinant Antibody; scFv Fragment (TAB-402CQ-S(P)) | ELISA | Mouse scFv |
TAB-148CQ-F(E) | Anti-Human TNF Recombinant Antibody Fab Fragment | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-254 | Anti-Human TNF Recombinant Antibody (Placulumab) | Neut, ELISA, IF, IP, FuncS, FC, ICC | [V-kappa]2 - Fc |
TAB-111CQ-F(E) | Anti-Human TNF Recombinant Antibody Fab Fragment (B5) | ELISA, WB | Human antibody |
TAB-113CQ-F(E) | Human Anti-TNF Recombinant Antibody; Fab Fragment (TAB-113CQ-F(E)) | ELISA | Human Fab |
TAB-133CQ-F(E) | Anti-Human TNF Recombinant Antibody Fab Fragment (2SD4) | ELISA, Neut | Human antibody |
TAB-142CQ-F(E) | Human Anti-TNF Recombinant Antibody; Fab Fragment (TAB-142CQ-F(E)) | ELISA, Neut | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-623CL | Bovine Anti-TNF Recombinant Antibody (TAB-623CL) | Neut | Bovine IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-124CQ | Human Anti-TNF Recombinant Antibody (TAB-124CQ) | FuncS, Neut | Humanized antibody |
TAB-125CQ | Human Anti-TNF Recombinant Antibody (TAB-125CQ) | ELISA, Neut | Humanized antibody |
TAB-126CQ | Human Anti-TNF Recombinant Antibody (TAB-126CQ) | ELISA, Neut | Humanized antibody |
TAB-127CQ | Human Anti-TNF Recombinant Antibody (TAB-127CQ) | ELISA, Neut | Humanized antibody |
TAB-128CQ | Human Anti-TNF Recombinant Antibody (TAB-128CQ) | ELISA, FuncS | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-083LC | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Non-hyper galactosylated) | ELISA, FC | Human antibody |
Gly-085LC | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Sialylated) | ELISA, FC | Human antibody |
Gly-086LC | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Hyper-galactosylated) | ELISA, FC | Human antibody |
Gly-087LC | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Hyper-galactosylated) | ELISA, FC | Human antibody |
Gly-163LC | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Sialylated) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-083LC-1 | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Non-hyper galactosylated) | ELISA, FC | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-085LC-1 | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Sialylated) | ELISA, FC | Human antibody |
Gly-163LC-1 | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Sialylated) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-086LC-1 | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Hyper-galactosylated) | ELISA, FC | Human antibody |
Gly-087LC-1 | Recombinant Anti-Human TNF Antibody (Fc glycosylation/Hyper-galactosylated) | ELISA, FC | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0609MZ | Chicken Anti-Tumor Necrosis Factor-α Polyclonal IgY | Indirect ELISA, WB | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-2051CQ | Mouse Anti-TNF Recombinant Antibody (clone CBL589) | ELISA, ICC, Neut | Mouse IgG1 |
NEUT-2052CQ | Mouse Anti-TNF Recombinant Antibody (clone CBL570) | WB, Neut | Mouse IgG2b |
NEUT-2105CQ | Mouse Anti-TNF Recombinant Antibody (clone MM0N1) | Neut | Mouse IgG1 |
NEUT-2106CQ | Mouse Anti-TNF Recombinant Antibody (clone CBL1023) | Neut | Mouse IgG1 |
NEUT-2107CQ | Mouse Anti-TNF Recombinant Antibody (clone TNF104C) | WB, FuncS, ELISA, FC, Neut | Mouse IgG2a |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-2057CQ | Rat Anti-Tnf Recombinant Antibody (clone XT3) | Block, ELISA, IHC, WB | Rat IgG1 |
NEUT-2070CQ | Mouse Anti-TNF Recombinant Antibody (clone 4F4) | Block, ELISA, ICC, IF, IHC, WB | Mouse IgG1 |
NEUT-2071CQ | Rabbit Anti-TNF Recombinant Antibody (clone 6E10) | Block, ELISA, IHC, WB | Rabbit IgG1 |
NEUT-2082CQ | Mouse Anti-TNF Recombinant Antibody (clone B-C7) | Block | Mouse IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-3602 | Rabbit Anti-Tnf Recombinant Antibody (clone DS3602AB) | ELISA, WB | Rabbit IgG |
MOR-4460 | Rabbit Anti-TNF Recombinant Antibody (clone SI554DS) | ELISA | Rabbit IgG |
MOR-4461 | Rabbit Anti-TNF Recombinant Antibody (clone SI555DS) | Neut | Rabbit IgG |
MOR-4751 | Rabbit Anti-Tnf Recombinant Antibody (clone TH265DS) | WB | Rabbit IgG |
MOR-4752 | Rabbit Anti-TNF Recombinant Antibody (clone TH266DS) | ELISA | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0007-YC-S(P) | Human Anti-TNF Recombinant Antibody (clone cA2); scFv Fragment | ELISA, Neut | Mouse scFv |
FAMAB-0332JF-S(P) | Mouse Anti-TNF Recombinant Antibody (clone Di62); scFv Fragment | RIA, ELISA, FuncS | Mouse scFv |
HPAB-2086-FY-S(P) | Mouse Anti-TNF Recombinant Antibody (clone 101.4); scFv Fragment | IA | Mouse scFv |
HPAB-2087-FY-S(P) | Mouse Anti-TNF Recombinant Antibody (clone CB0010); scFv Fragment | Neut | Mouse scFv |
HPAB-1564WJ-S(P) | Mouse Anti-TNF Recombinant Antibody; scFv Fragment (clone 3B10) | ELISA, WB, Neut | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0007-YC-F(E) | Human Anti-TNF Recombinant Antibody (clone cA2); Fab Fragment | ELISA, Neut | Human Fab |
HPAB-1283LY-F(E) | Human Anti-TNF Recombinant Antibody (clone CBL026); Fab Fragment | ELISA | Human Fab |
HPAB-M0680-YC-F(E) | Human Anti-TNF Recombinant Antibody; Fab Fragment (HPAB-M0680-YC-F(E)) | ELISA, Neut, Inhib | Humanized Fab |
HPAB-M0681-YC-F(E) | Human Anti-TNF Recombinant Antibody; Fab Fragment (HPAB-M0681-YC-F(E)) | ELISA, Neut, Inhib | Humanized Fab |
HPAB-0203-WJ-F(E) | Rat Anti-TNF Recombinant Antibody; Fab Fragment (HPAB-0203-WJ-F(E)) | Neut, ELISA | Rat Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-768 | Afuco™ Anti-TNF ADCC Recombinant Antibody (Nerelimomab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC, IP | ADCC enhanced antibody |
AFC-TAB-006 | Afuco™ Anti-TNF ADCC Recombinant Antibody (Infliximab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-010 | Afuco™ Anti-TNF ADCC Recombinant Antibody (AFC-TAB-010), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-AP531-YC | Camel Anti-TNF Recombinant Antibody (HPAB-AP531-YC) | ELISA | Camel VHH |
HPAB-AP532-YC | Camel Anti-TNF Recombinant Antibody (HPAB-AP532-YC) | ELISA | Camel VHH |
HPAB-AP533-YC | Camel Anti-TNF Recombinant Antibody (HPAB-AP533-YC) | ELISA | Camel VHH |
HPAB-AP534-YC | Camel Anti-TNF Recombinant Antibody (HPAB-AP534-YC) | ELISA | Camel VHH |
HPAB-AP535-YC | Camel Anti-TNF Recombinant Antibody (HPAB-AP535-YC) | ELISA | Camel VHH |
There are currently no Customer reviews or questions for AFC-601CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.